Navigation Links
Kosan's Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
Date:8/19/2007

HAYWARD, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN) today announced that Pfizer Inc. has initiated a Phase 1 clinical trial of motilin receptor agonist PF-04548043, formerly KOS-2187, a selective and potent motilin receptor agonist being developed for the treatment of gastroesophageal reflux disease (GERD) and potentially other gastrointestinal (GI) disorders. The Phase 1 clinical trial is designed to test the safety, tolerability and pharmacokinetics of PF-04548043 in healthy subjects. In December 2006, Kosan and Pfizer established a worldwide license agreement for Kosan's motilin agonist program, including KOS-2187 and related compounds, in a transaction potentially valued at $250 million for the successful development and commercialization of PF-04548043 for one indication as well as royalties on worldwide sales.

"Kosan today has four advancing clinical programs, underscoring the increasing value of our development pipeline," said Robert G. Johnson, Jr., M.D., Ph.D., Kosan's President and Chief Executive Officer. "Consistent with Kosan's focus on oncology, we successfully out-licensed KOS-2187 and our motilin receptor agonist program to Pfizer, a company with a strong gastrointestinal capability that could best exploit its therapeutic and commercial potential. We appreciate Pfizer's commitment to the development and potential commercialization of this promising prokinetic compound and look forward to its rapid advancement through the clinic."

About PF-04548043 and Motilin Receptor Agonists

Motilin, a hormone secreted by the small intestine, stimulates gastrointestinal motility (movement). The activity of motilin is mediated through the G-protein coupled
'/>"/>

SOURCE Kosan Biosciences Incorporated

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
2. Human Genome Sciences Reports Growing Evidence That Its TRAIL Receptor Antibodies Have Significant Potential in the Treatment of a Broad Range of Cancers
3. First Controlled Large-Scale Intervention Angiotensin Receptor Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study Demonstrates Significant Reduction in Blood Pressure and Protection of Organs with Valsartan
4. Positive Results Using Affitech-Identified Human Antibody That Blocks VEGF Binding to VEGF Receptor 2 in Preclinical Cancer Model Reported by Peregrine
5. Portola Pharmaceuticals Presents Positive Phase I Data of Its ADP Receptor Antagonist at the American College of Cardiology
6. Schering-Plough Announces Presentation of Phase II Trial Results for Novel Oral Thrombin Receptor Antagonist at the 2007 Annual Meeting of The American College of Cardiology/i2 Summit
7. Weight Management is Not Enough for Cannabinoid Type 1 (CB1) Receptor Antagonists to Become a Commercial Success
8. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
9. GlaxoSmithKline’s Hib-MenCY-TT Combination Vaccine Meets Phase II Study Endpoints of Immunogenicity and Safety Compared to Licensed Vaccines
10. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
11. Mode of Action of EpiCept-Licensed Cancer Compound Profiled at AACR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... Report Details Ovarian Cancer ... Changes and Emerging Opportunities What,s the future for ... study forecasts those pharmaceutical revenues. There you find ... also explore trends, results, treatments, R&D, and opportunities, ... predictions to 2025 at overall world market, submarket, ...
(Date:9/3/2015)... LONDON , Sept. 3, 2015 ... ophthalmic devices market? Which areas are going to grow ... you potential revenues to 2025, assessing data, trends, opportunities ... 176 tables, charts, and graphs. Discover the most lucrative ... Our new study lets you assess forecasted sales at ...
(Date:9/3/2015)... 3, 2015 Report Details ... that Market, its R&D and Sales Potentials ... of cancer-treating medicines? Visiongain,s new report gives you revenue predictions ... you discover financial data, R&D trends, opportunities, interviews and revenue ... analysis you see forecasted sales to 2025 at overall world ...
Breaking Medicine Technology:Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential 2Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential 3Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential 4Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential 5Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential 6Ophthalmic Devices Market Forecast 2015-2025: Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 2Ophthalmic Devices Market Forecast 2015-2025: Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 3Ophthalmic Devices Market Forecast 2015-2025: Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 4World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 2World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 3World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 4World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 5World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 6World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 7
... Australia, July 26, 2011 Ceridia Pty Ltd., ... therapeutic drugs, announce the successful completion of Phase ... formulation, CER006.  CER006 was designed to be a ... Ceridia,s LipoCeramic reformulation technology but also to attain ...
... VIEW, Calif., July 26, 2011 Alexza Pharmaceuticals, ... will report financial results for the quarter ended June 30, ... the U.S. financial markets.  Alexza also announced that the resubmission ... Food and Drug Administration (FDA) is now planned for Monday, ...
Cached Medicine Technology:Australian Biotech Ceridia Pty Ltd Completes Successful Human Clinical Trial 2Alexza to Announce 2011 Second Quarter Financial Results on Monday, August 8, 2011 2Alexza to Announce 2011 Second Quarter Financial Results on Monday, August 8, 2011 3Alexza to Announce 2011 Second Quarter Financial Results on Monday, August 8, 2011 4
(Date:9/3/2015)... ... September 03, 2015 , ... Real Time Pain Relief (RTPR), makers ... rider David Mason has signed an official endorsement deal with the company. Originally from ... and his first bull at 15. He is an Australian bull riding champion, following ...
(Date:9/3/2015)... ... 2015 , ... Hope For The Warriors® is pleased to ... awarded two times each year to spouses or caregivers of post-9/11 wounded or ... restoring a sense of self, restoring the family unit, and restoring hope for ...
(Date:9/3/2015)... ... September 03, 2015 , ... For ... compression garments. However, graduated compression garments are an effective solution for reducing the ... Robyn Bjork, was recently sponsored by SIGVARIS for a unique opportunity ...
(Date:9/3/2015)... ... September 03, 2015 , ... ... by connecting accredited and institutional investors to real estate investment opportunities nationwide, today ... meet demand from both investors and sponsoring real estate companies. , ...
(Date:9/3/2015)... Louis, MO (PRWEB) , ... September 03, 2015 , ... ... Nightly News*, covering the allegations made by IVC filter lawsuits filed against ... they were harmed when a Bard IVC filter broke or failed, have recently been ...
Breaking Medicine News(10 mins):Health News:Real Time Pain Relief Sponsors the Talented PBR Bull Rider from Down Under - David Mason 2Health News:Real Time Pain Relief Sponsors the Talented PBR Bull Rider from Down Under - David Mason 3Health News:Hope For The Warriors Spouse/Caregiver Scholarships Now Open for Spring 2016 2Health News:SIGVARIS Supports the Lymphedema Treatment Act to Help Patients with Lymphedema 2Health News:SIGVARIS Supports the Lymphedema Treatment Act to Help Patients with Lymphedema 3Health News:RealtyShares Announces Mezzanine Financing Products 2Health News:RealtyShares Announces Mezzanine Financing Products 3Health News:Bard IVC Lawsuit Allegations Reach National Prime Time News 2Health News:Bard IVC Lawsuit Allegations Reach National Prime Time News 3
... medication-related problems, including under treatment, suboptimal drugs, suboptimal dosing, ... quality of life. Now new research (1), from the ... North Carolina at Chapel Hill shows that blacks have ... regimens is a particular issue for this group. Dr. ...
... Claimant states ... ... has filed a lawsuit against Covidien, formerly Tyco Healthcare, for allegedly discriminating against and ... disability. The lawsuit was filed under California’s version of the Americans with Disabilities Act (ADA). ...
... , , WASHINGTON, Dec. 14 ... key factors affecting youth violence, with more than 30 ... and music provoke violence. Gangs, drugs and bullying are ... according to the National Campaign to Stop Violence. , ...
... teens have died trying to achieve euphoric state, experts warn ... of U.S. doctors have never heard of the "choking game" ... signs of the potentially lethal past-time. , Also known as ... among other monikers, the activity involves intentionally trying to strangle ...
... , , ... meridianEMR announced today that they have successfully integrated their EMR ... ) , As the U.S. ramps up the implementation of ... errors, and improve patient care, meridianEMR and LABORIE MEDICAL have ...
... A new ... as motivational words which is also known to some as, inspiring words. It’s called Mutual ... (PRWEB) December 13, ... of his newly published book in London, UK on Thursday, said encouraging words have a ...
Cached Medicine News:Health News:Racial differences in medication use 2Health News:Samuelson, Wilson & Roe Sues Covidien for Alleged Disability Discrimination 2Health News:Samuelson, Wilson & Roe Sues Covidien for Alleged Disability Discrimination 3Health News:Middle Schoolers Identify Violent Content in Youth-Targeted Entertainment as a Strong Influence in Causing Youth Violence 2Health News:Middle Schoolers Identify Violent Content in Youth-Targeted Entertainment as a Strong Influence in Causing Youth Violence 3Health News:Middle Schoolers Identify Violent Content in Youth-Targeted Entertainment as a Strong Influence in Causing Youth Violence 4Health News:Many Doctors Unaware of Deadly 'Choking Game' 2Health News:Many Doctors Unaware of Deadly 'Choking Game' 3Health News:LABORIE Announces Its Urodynamic Systems Integration with meridianEMR 2Health News:Encouragement Words Takes on a New Terminology as Myeexpert Gifts Books, and Offers Free Counselling 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: